Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancerDaniela Massihnia(University of Palermo), Elisa Giovannetti(University of Pisa)Journal of Hematology & OncologyJanuary 6, 201710.1186/s13045-016-0371-1Cited by 84SaveCiteExport RISWatch citationsRelated PapersRole of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells|Cancers|2019|76NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor|Oncotarget|2015|31Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC)|Cancers|2023|31Biodegradable Ultrasmall-in-Nano Architectures Loaded with Cisplatin Prodrug in Combination with Ionizing Radiation Induces DNA Damage and Apoptosis in Pancreatic Ductal Adenocarcinoma|Cancers|2022|215'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer|Oncotarget|2018|16